Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

被引:20
|
作者
Wulffelé, MG
Kooy, A
Lehert, P
Bets, D
Donker, AJM
Stehouwer, CDA
机构
[1] Bethesda Gen Hosp, Dept Internal Med, NL-7909 AA Hoogeveen, Netherlands
[2] FUCAM, Dept Stat, Fac Econ, Mons, Belgium
[3] E Merck Nederland BV, Clin Res & Dev, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands
[6] Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands
关键词
blood pressure; metformin; randomized controlled trial; Type; 2; diabetes; 24-h ambulatory blood pressure monitoring;
D O I
10.1111/j.1464-5491.2005.01554.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated in a double-blind study whether metformin reduces blood pressure (BP) in patients with Type 2 diabetes intensively treated with insulin. Methhods A total of 220 patients with Type 2 diabetes were asked to undergo 24-h ambulatory BP monitoring (24-h ABPM). One hundred and eighty-two gave informed consent. Eighty-nine were randomized to metformin and 93 to placebo. Thirty-five subjects dropped out (13 placebo, 22 metformin users); 147 patients underwent a second 24-h ABPM, 16 weeks after randomization. Results Systolic BP (SBP), diastolic BP (DBP), pulse BP (PP), mean BP (MP) and heart rate (HR) were measured as office BP measurements and as 24-h ABPM for 24-h, day and night. Office BP measurements did not differ significantly between the placebo- and metformin-treated groups for any BP measure, but showed a non-significant trend for SBP reduction with metformin use (mean baseline-adjusted difference, metformin minus placebo: -4.2 mmHg, 95% CI, -9.9 to +1.5; P = 0.15). The baseline-adjusted differences of the ambulatory measurements were -0.2 mmHg (95% CI, -2.9 to +2.6) for the 24-h SBP, and +1.1 mmHg (95% CI, -0.7 to +2.8) for the 24-h DBP. On the whole, BP differences between metformin- and placebo-treated groups were not statistically significant. The only significant difference was for night-time PP (baseline-adjusted difference: -2.2 mmHg; 95% CI, -4.2 to -0.2). These results were not different after adjustment for age and diabetes duration, or for (changes in) body mass index, glycated haemoglobin, insulin dose or plasma homocysteine. Conclusion Metformin does not significantly affect BP in patients with Type 2 diabetes intensively treated with insulin.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [1] Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?
    Dziegielewska-Gesiak, Sylwia
    Fatyga, Edyta
    Pilot, Magdalena
    Wierzgon, Aleksander
    Muc-Wierzgon, Malgorzata
    DIABETES METABOLIC SYNDROME AND OBESITY, 2022, 15 : 3589 - 3599
  • [2] Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes
    Borg, Malcolm J.
    Jones, Karen L.
    Sun, Zilin
    Horowitz, Michael
    Rayner, Christopher K.
    Wu, Tongzhi
    DIABETES OBESITY & METABOLISM, 2019, 21 (05) : 1251 - 1254
  • [3] Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
    Ponssen, HH
    Elte, JWF
    Lehert, P
    Schouten, JP
    Bets, D
    CLINICAL THERAPEUTICS, 2000, 22 (06) : 709 - 718
  • [4] Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
    Hermann, LS
    Kalén, J
    Katzman, P
    Lager, I
    Nilsson, A
    Norrhamn, O
    Sartor, G
    Ugander, L
    DIABETES OBESITY & METABOLISM, 2001, 3 (06) : 428 - 434
  • [5] A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients
    Pala, L.
    Mannucci, E.
    Dicembrini, I.
    Rotella, C. M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (01) : 132 - 135
  • [6] Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
    Stage, Tore Bjerregaard
    Christensen, Mette-Marie Hougaard
    Jorgensen, Niklas Rye
    Beck-Nielsen, Henning
    Brosen, Kim
    Gram, Jeppe
    Frost, Morten
    BONE, 2018, 112 : 35 - 41
  • [7] Fulminant lactic acidosis in two patients with Type 2 diabetes treated with metformin
    Brassoe, R
    Elkmann, T
    Hempel, M
    Gravholt, CH
    DIABETIC MEDICINE, 2005, 22 (10) : 1451 - 1453
  • [8] Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial
    Hansen, Christian Stevns
    Lundby-Christiansen, Louise
    Tarnow, Lise
    Gluud, Christian
    Hedetoft, Christoffer
    Thorsteinsson, Birger
    Hemmingsen, Bianca
    Wiinberg, Niels
    Sneppen, Simone B.
    Lund, Soren S.
    Krarup, Thure
    Madsbad, Sten
    Almdal, Thomas
    Carstensen, Bendix
    Jorgensen, Marit E.
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [9] Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes
    Kabadi, Udaya M.
    Kabadi, Mary
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 72 (03) : 265 - 270
  • [10] Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
    Lingvay, Ildiko
    Raskin, Philip
    Szczepaniak, Lidia S.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 137 - 142